Data edition of
Residue An evidence-graded reference for peptide science

Comparisons

Where a randomized head-to-head trial exists, we lead with it. Where none does, we say so, and keep each compound's numbers in its own trial's context rather than ranking across studies.

Two identical glass beakers, one holding pale amber liquid and one clear, standing either side of a brass balance
  1. A A Semaglutide vs Tirzepatide In both head-to-head randomized trials, tirzepatide came out ahead on the primary endpoint.
  2. D A AOD-9604 vs Tesamorelin Both are linked to fat loss, on very different evidence.
  3. C D BPC-157 vs TB-500 Both are research peptides linked to tissue repair; neither is FDA-approved.
  4. B A Cagrilintide vs Semaglutide Cagrilintide is an investigational long-acting amylin analog; semaglutide is an FDA-approved GLP-1 receptor agonist.
  5. C C CJC-1295 vs Ipamorelin CJC-1295 is a long-acting GHRH analog: one injection raised growth hormone 2–10-fold for six days or more in healthy adults.
  6. A D Elamipretide vs MOTS-c Both are linked to mitochondria but are otherwise unalike.
  7. A C Afamelanotide vs Melanotan II Both are synthetic α-MSH analogs, but only one became a medicine.
  8. A C Bremelanotide vs Melanotan II PT-141 (bremelanotide) and Melanotan II are closely related: PubChem lists the same seven-residue sequence for both.
  9. B A Retatrutide vs Semaglutide Semaglutide is an FDA-approved GLP-1 receptor agonist with a cardiovascular-outcomes trial behind it; retatrutide is an investigational GIP, GLP-1 and glucagon receptor agonist.
  10. B A Retatrutide vs Tirzepatide Tirzepatide activates GIP and GLP-1 receptors and is FDA-approved; retatrutide adds the glucagon receptor and is still investigational.
  11. C C Selank vs Semax Selank and semax are synthetic heptapeptides studied mainly in Russia.
  12. A C Sermorelin vs Ipamorelin Both raise growth hormone, through different receptors.
  13. A C Tesamorelin vs Ipamorelin Both raise growth hormone, by different routes.
  14. A A Tesamorelin vs Sermorelin Both are synthetic analogs of growth-hormone-releasing hormone (GHRH) that prompt the pituitary to release growth hormone.

How should these comparisons be read?

The two badges on each card are the headline evidence grades of the two compounds, from A (FDA-approved on adequate human trials) to D (preclinical only); see the grading methodology. A grade describes the published record for a molecule, not any product sold under its name.

Only a few pairs have been tested against each other in one randomized trial. For every other pair, each column reports that compound's own trials, in their own populations and doses, and the page says so. Figures from different trials are not comparable, so we never rank compounds across studies.